Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:34:02.466Z.
Calculation as of: 2026-10-06T15:34:02.466Z.
Quote observation: 2026-10-06T15:31:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cbfdb9b702203632c67f1d3ce56f9042d1c779579fe07ac28526a5c99bc9a0a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$449.16M
EBITDA Yield
224.38%
TTM Avg
150.45%
3Y Avg
150.45%
5Y Avg
150.45%
Market Cap
$454.47M
EBITDA Yield
N/A
TTM Avg
702.73%
3Y Avg
702.73%
5Y Avg
702.73%
Market Cap
$454.18M
EBITDA Yield
N/A
TTM Avg
8.61%
3Y Avg
13.81%
5Y Avg
19.64%
Market Cap
$425.48M
EBITDA Yield
N/A
TTM Avg
6.82%
3Y Avg
6.82%
5Y Avg
6.82%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $442.61M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $444.80M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $438.13M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $449.16M | 224.38% | 150.45% | 150.45% | 150.45% |
| Ovid Therapeutics Inc. (OVID)vs › | $454.47M | N/A | 702.73% | 702.73% | 702.73% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $454.18M | N/A | 8.61% | 13.81% | 19.64% |
| NeoGenomics, Inc. (NEO)vs › | $434.25M | N/A | 1.44% | 5.28% | 7.05% |
| Prothena Corporation plc (PRTA)vs › | $425.48M | N/A | 6.82% | 6.82% | 6.82% |
| NRC Health (NRC)vs › | $461.38M | 4.26% | 6.53% | 7.37% | 6.54% |
| Kamada Ltd. (KMDA)vs › | $467.32M | 9.59% | 10.23% | 10.38% | 8.34% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
